Piper Sandler initiated coverage of Compass Therapeutics (CMPX) with an Overweight rating and $12 price target The company is developing a suite of antibody programs in oncology across pivotal Phase 2/3 to preclinical stage, the analyst tells investors in a research note. The firm says Compass’ lead program, tovecimig, is set for a data readout from its pivotal Phase 2/3 trial in March, and prior data suggests the trial should report efficacy supporting regulatory approval. This is a “compelling” near-term catalyst for the shares, contends Piper.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Buy Rating for Compass Therapeutics Driven by Promising Tovecimig Results and Strategic Pipeline
- Two new option listings on February 11th
- Optimistic Buy Rating for Compass Therapeutics Due to Promising CTX-009 Trial Results and Market Potential
- Compass Therapeutics price target raised to $8 from $7 at Jefferies
- Compass Therapeutics provides corporate update, CTX-009 advances